1,3,3-trimethyl-6-azabicyclo[3.2.1]octane | 651341-79-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: 1,3,3-trimethyl-6-azabicyclo[3.2.1]octane
• 英文别名: 6-Azabicyclo[3.2.1]octane, 1,3,3-trimethyl-, (1R,5S)-；(1R,5S)-1,3,3-trimethyl-6-azabicyclo[3.2.1]octane
• CAS: 651341-79-6
• 化学式: C₁₀H₁₉N
• 分子量: 153.268
• InChiKey: FRAKHUZTNLUGPB-WPRPVWTQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (4-bromo-2-fluorophenyl)(hydroxy)acetic acid 、 1,3,3-trimethyl-6-azabicyclo[3.2.1]octane 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.17h， 以88.65%的产率得到1-(4-bromo-2-fluorophenyl)-2-oxo-2-(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)ethanol
  参考文献：
  名称：

  Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same

  摘要：

  本发明涉及11-β羟基类固醇脱氢酶1型的抑制剂及其药物组合物。本发明的化合物可用于治疗与11-β羟基类固醇脱氢酶1型的表达或活性相关的各种疾病。

  公开号：

  US20070213311A1

文献信息

• Antitumoural therapies
  申请人：Lytix Biopharma AS

  公开号：EP2338522A1

  公开（公告）日：2011-06-29

  The invention relates to a peptide consisting of 2-4 amino acids comprising at least three lipophilic groups of at least 5 non-hydrogen atoms wherein one of the molecule's lipophilic groups incorporates 6 or more non-hydrogen atoms and a second lipophilic group incorporates 10 or more non-hydrogen atoms and wherein at least one lipophilic group incorporates a closed ring of at least 6 non-hydrogen atoms, said peptide having at least one more cationic than anionic moiety, and wherein at least one of the amino acids has a cationic side chain (R group) and at least one of the lipophilic groups is an amino acid side chain (R group), for use as an antitumoural agent and to a peptide consisting of 2-4 amino acids comprising a lipophilic group comprising at least 13 non-hydrogen atoms and one or more closed rings of 4 or more non-hydrogen atoms, wherein at least one of the amino acids has a cationic side chain (R group) and at least one of the amino acid side chains (R groups) is a lipophilic group of at least 4 non-hydrogen atoms, said peptide having at least two more cationic than anionic moieties, also for use as an antitumoural agent.

  本发明涉及一种由 2-4 个氨基酸组成的多肽，这些氨基酸至少包含三个亲脂基团，其中一个分子的亲脂基团包含 6 个或更多的非氢原子，第二个亲脂基团包含 10 个或更多的非氢原子，并且至少有一个亲脂基团包含至少 6 个非氢原子的闭环、所述肽具有至少一个阳离子多于阴离子的分子，其中至少一个氨基酸具有阳离子侧链（R 基团），至少一个亲脂基团是氨基酸侧链（R 基团）、用于抗肿瘤剂的肽，由 2-4 个氨基酸组成，其中亲脂基团包括至少 13 个非氢原子和一个或多个由 4 个或更多非氢原子组成的闭环、其中至少有一个氨基酸具有阳离子侧链（R 基团），至少有一个氨基酸侧链（R 基团）是由至少 4 个非氢原子组成的亲脂基团，所述肽具有至少两个阳离子多于阴离子的分子，也可用作抗肿瘤剂。
• ANTIMICROBIAL COMPOUNDS AND FORMULATIONS
  申请人：Lytix Biopharma AS

  公开号：EP1263471B1

  公开（公告）日：2011-10-12
• Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
  申请人：Li Yun-Long

  公开号：US20070213311A1

  公开（公告）日：2007-09-13

  The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1.

  本发明涉及11-β羟基类固醇脱氢酶1型的抑制剂及其药物组合物。本发明的化合物可用于治疗与11-β羟基类固醇脱氢酶1型的表达或活性相关的各种疾病。